Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) – Pipeline Review, H2 2016’, provides in depth analysis on Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted pipeline therapeutics.

The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3)

The report reviews Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics and enlists all their major and minor projects

The report assesses Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc.

Axxam SpA

Bionomics Limited

conoGenetix biosciences GmbH

Johnson & Johnson

KPI Therapeutics, Inc.

Sevion Therapeutics, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Overview 7

Therapeutics Development 8

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Stage of Development 8

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Therapy Area 9

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Indication 10

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Products Glance 12

Early Stage Products 12

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Companies 13

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Universities/Institutes 16

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Companies Involved in Therapeutics Development 24

Amgen Inc. 24

Axxam SpA 25

Bionomics Limited 26

conoGenetix biosciences GmbH 27

Johnson & Johnson 28

KPI Therapeutics, Inc. 29

Sevion Therapeutics, Inc. 30

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Drug Profiles 31

BNC-164 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

cgtx-A - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

cgtx-F - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

cgtx-G - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

dalazatide - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

KPI-150 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

KPI-190 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

OSK-1 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Diseases - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules to Block Kv1.3 Ion Channel for Multiple Sclerosis, Immunology, Inflammatory Bowel Disease and Type 1 Diabetes - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

SVN-001 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Synthetic Peptides to Block Potassium Voltage-Gated Channel Subfamily A Member 3 (Kv1.3) for Autoimmune Disorders - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Dormant Projects 48

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Featured News & Press Releases 50

Jun 20, 2016: Dalazatide as a Potential Immunotherapy for Lupus to be Presented at Immunology Conference 50

Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus 50

May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus 51

May 12, 2016: KPI Therapeutics Presents Dalazatide Plaque Psoriasis Data at Dermatology Conference 51

Apr 18, 2016: KPI Therapeutics to Present Dalazatide Plaque Psoriasis Data at Dermatology Conference 51

Mar 21, 2016: KPI Therapeutics Presents Promising Data on KPI-190 as Potential Therapy for Uveitis, Autoimmune Eye Diseases 52

Mar 14, 2016: KPI Therapeutics to Present Dalazatide Data as Potential Therapy for Uveitis, Autoimmune Eye Diseases at Ocular Conference 52

Feb 08, 2016: KPI Therapeutics Initiates Research Program In Skin Diseases 52

Feb 08, 2016: KPI Therapeutics Initiates Research Program In Eye Diseases 53

Feb 03, 2016: KPI Invited to Present at BIO CEO & Investor in NYC 53

Nov 10, 2015: Kineta, Seattle Children’s Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus 54

Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting 54

Sep 21, 2015: Kineta Chief Scientist to Speak on Dalazatide Clinical Results, Potential Therapy for Autoimmune Diseases at Basel Life Science Week 55

Aug 08, 2015: Kineta Presents Updated Data on Dalazatide Clinical Trial at 12th World Congress on Inflammation 55

Jul 08, 2015: Kineta Chief Scientist Invited to Speak on Dalazatide Phase 1 B Clinical Trial 56

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by Amgen Inc., H2 2016 24

Pipeline by Axxam SpA, H2 2016 25

Pipeline by Bionomics Limited, H2 2016 26

Pipeline by conoGenetix biosciences GmbH, H2 2016 27

Pipeline by Johnson & Johnson, H2 2016 28

Pipeline by KPI Therapeutics, Inc., H2 2016 29

Pipeline by Sevion Therapeutics, Inc., H2 2016 30

Dormant Projects, H2 2016 48

Dormant Projects (Contd..1), H2 2016 49

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports